Abbott, a global healthcare leader, announced the launch of the International Cardio‑Renal Risk Assessment and Stratification (ICRAS) Tool, an innovative web‑based tool designed to help doctors across India to identify heart and kidney risks in people living with Type 2 Diabetes Mellitus (T2DM).
Developed with guidance from a distinguished expert panel — Dr. Sanjay Kalra, Dr. V. Mohan, Dr. Atul Dhingra, Dr. Deep Dutta, Dr. Dinesh Khullar, Dr. Jothydev Kesavadev, Dr. K. D. Modi, Dr. Manash P. Baruah, Dr. Nitin Kapoor, Dr. Pramila Kalra, Dr. Shehla Shaikh and Dr. Tiny Nair — the ICRAS Tool will help clinicians assess cardio‑renal risk early in people living with T2DM. By early risk stratification, the tool aims to improve health outcomes and reduce complications associated with T2DM.
India is often referred to as the “diabetes capital of the world,” with 101 million people currently living with diabetes¹. Heart and kidney conditions remain among the most common and serious complications of Type 2 diabetes². This makes early risk assessment especially important.
Dr. Kartik Peethambaran, Medical Director, Abbott India, said:
“Abbott remains committed to transforming diabetes care delivery across the entire healthcare ecosystem. For this, we continue to partner with healthcare professionals to support appropriate patient screening and improve clinical outcomes. The ICRAS tool is designed to help clinicians assess a diabetic patient’s likelihood of developing Diabetic Kidney Disease (DKD), Coronary Heart Disease (CHD), and Major Adverse Cardiovascular Events (MACE)³. What makes this tool particularly impactful is its ability to enable timely clinical decision‑making, supporting evidence‑based practice, and strengthening overall patient evaluation.”
The ICRAS Tool brings together important health indicators — including key medical test results and lifestyle factors — to generate separate risk scores for kidney disease, heart disease, and major cardiac events in people with Type 2 diabetes. It also accounts for gender‑specific differences in risk, offering a clearer and more personalized summary of each diabetic patient’s risk of developing heart and kidney condition. Designed with privacy at its core, this web‑based tool does not capture any personal information about patients or doctors, ensuring all assessments remain fully secure. Dr. Sanjay Kalra, Consultant Endocrinologist, Bharti Hospital, Karnal added :
“Diabetes complications often develop because of a combination of high blood glucose, excess weight, other health conditions, and daily lifestyle habits. Over time, in diabetic patients these factors can put extra strain on the heart and kidneys — which are among the organs most affected in Type 2 diabetes². Nearly one‑third of people with Type 2 diabetes have some form of heart disease², and chronic kidney disease affects 40% of T2DM patients⁴. The challenge is that many people feel fine early on, even when complications may already be developing silently. Timely risk assessments can help doctors spot these issues sooner and act before they become serious.”
Early identification of diabetes-related heart and kidney risks allows doctors to tailor care in meaningful ways. Timely, targeted interventions can slow or even prevent serious heart and kidney complications — helping people living with diabetes stay healthier for longer.
1. Gupta M, Singh R, Lehl SS. Diabetes in India: a long way to go. Int J Sci Rep [Internet]. 2015 May 1 [cited 2026 Mar. 5];1(1):1-2. “
2. Sugandh F, Chandio M, Raveena F, Kumar L, Karishma F, Khuwaja S, et al. Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine. Cureus. 15(8): e43697.
3. Evans M, Morgan AR, Patel D, Dhatariya K, Greenwood S, Newland-Jones P, et al. Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications. Diabetes Ther. 2021 Jan 1;12(1):87–105)
4 Cardio-renal protection in type 2 diabetes IDF Technical Working Group et al. Diabetes Research and Clinical Practice, Volume 222, 112150
Disclaimer – The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
Issued by Abbott Healthcare Private Limited (“Abbott”) for general awareness and not a substitute for doctor’s advice. ICRAS Tool is meant to be used only by qualified healthcare professionals. The views expressed by independent doctors are their independent professional judgment. Rest of the information is based on scientific references. Although due care has been taken to ensure the accuracy and completeness of the information, Abbott shall not be liable in any manner whatsoever for any action based on the information provided in this article and does not hold itself liable for any consequences, legal or otherwise, arising out of information in this article. Please consult qualified healthcare professionals for more information.
